Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer
JCO Oncology Practice · 2024
DOI: 10.1200/op.23.00602 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2024. Verfasst von Aaron P Mitchell und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Bone Neoplasms, Prostatic Neoplasms, Osteoporosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
PURPOSE Bone-modifying agents (BMAs) do not prevent skeletal-related events among patients with castration-sensitive prostate cancer (CSPC), but many patients receive BMAs unnecessarily. The costs to Medicare from overuse have not been assessed. METHODS We used linked SEER-Medicare data 2011-2015 to measure the frequency and number of doses of zoledronic acid (ZA) and denosumab received during CSPC (between diagnosis and initiation of metastatic, castration resistant prostate cancer therapy). We estimated excess BMA among patients who received BMA therapy for CSPC and did not have an indication for osteoporosis fracture prevention. We used the Medicare fee schedule for drug prices and peer-reviewed sources to estimate adverse event frequencies and costs. RESULTS Median CSPC duration was 387 days (IQR, 253-573), during which time 42% of patients received ≥one dose of denosumab (mean doses, 7) and 18% received ≥one dose of ZA (mean doses, 7). Thirty-eight percent of those receiving denosumab and 47% of those receiving ZA had a history of osteoporosis, osteopenia, spine or hip fracture, or hypercalcemia. The estimated, annual excess BMA cost to Medicare was $44,105,041 in US dollars (USD), composed of $43,303,078 USD and $45,512 USD in drug costs for denosumab and ZA, respectively, and $682,865 USD and $75,585 USD in adverse event costs, respectively. In one-way sensitivity analysis, the estimate was most sensitive to denosumab dosing frequency (estimate range, $28,469,237 USD-$98,830,351 USD) and duration of CSPC (estimate range, $36,823,311 USD-$99,015,908 USD). CONCLUSION BMA overuse in CSPC incurs substantial cost to Medicare, largely because of denosumab drug costs. Excess costs may be reduced by greater adherence to guideline-concordant BMA use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Medicine, Division of Subspecialty Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
ORCID-Profile: Aaron P Mitchell, David Nemirovsky, Akriti Mishra Meza, Sonia Persaud, Michael J Morris
Förderung
- NCI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Mitchell, A. P., Nemirovsky, D., Mishra Meza, A., Chakraborty, N., Persaud, S., Farooki, A., & Morris, M. J. (2024). Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer. JCO Oncology Practice. https://doi.org/10.1200/op.23.00602
Vancouver
Mitchell AP, Nemirovsky D, Mishra Meza A, Chakraborty N, Persaud S, Farooki A, et al. Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer. JCO Oncology Practice. 2024. doi:10.1200/op.23.00602
BibTeX
@article{Mitchell2024,
author = {Mitchell, Aaron P and Nemirovsky, David and Mishra Meza, Akriti and Chakraborty, Nirjhar and Persaud, Sonia and Farooki, Azeez and Morris, Michael J},
title = {Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer},
journal = {JCO Oncology Practice},
year = {2024},
doi = {10.1200/op.23.00602}
}
EUVIMED